Precision Oncology

Cancer is a genetic disease, caused by changes in the DNA that control the function of the cell, as well as its growth and division.

At IOB, we offer our patients the possibility to benefit from precision oncology through various genomic platforms adapted to the needs of each case .

These platforms do not only allow us to search for tumor type genetic alterations, but also provide us with the ability to make a personalized therapeutic recommendation with the greatest probability of success, enabling us to offer the patient the more suitable treatment for their pathology, based on their genetic, clinical and molecular profile.

This makes it possible to use more efficient and safer drugs, matching them to patients based on the presence or lack thereof of certain biomarkers. That way we can incorporate those treatments that patients have a greater probability of responding to, using highly selective medications and creating a personalized individual treatment. 

That is why, at IOB, we believe in the transverse approach to the treatment of cancer, which consists in the identification of the specific genetic alteration in order to ensure a specific and selective treatment that provides maximum benefits to the patient and does not depend on the organ in which the cancer originated.

At the IOB, we offer different tests that make precision oncology possible, such as the liquid biopsy and the genetic test.

Liquid biopsy

Liquid biopsy, non-invasive cancer diagnostics, personalized treatment and follow-up

Liquid biopsy is a non-invasive diagnostic technique for cancer in which all that is needed is to take one or several blood samples. In which tumor cells are look for, , allowing early-stage diagnosis. The use of this technique avoids unnecessary discomfort for the patient and saves both time and resources.

Furthermore, in patients who already have cancer, it allows the monitoring of the disease’s evolution and the planning and personalization of the treatment.

PERSONALIZED TREATMENT, MONITORING AND VALIDATION OF THE THERAPY

Liquid biopsy is a “new diagnostic technique that, on one hand allows us to detect mutations in the tumor within the blood and thus determine what is the best treatment for the patient, while at the same time, it allows us to monitor whether those same treatments are working or not.”– Aleix Prat

ADVANTAGES OF LIQUID BIOPSY

Genetic tests

With genetic tests we can anticipate any possible alterations and take early action to avoid complications or obtain more effective treatments, as well as getting ahead of the development of cancer.

Genetic analysis can reveal mutations in the genes that can provide important information for the diagnosis, treatment and prevention of cancer.

That is why, at IOB, we use this tool to achieve greater efficacy in the treatment of our patients. The result of the genomic test will be evaluated by a multidisciplinary committee and you will receive a report with the detected genomic alterations in your tumor and the targeted therapies and clinical trials that are best suited based on scientific evidence and your particular clinical situation. 

Hereditary cancer

Hereditary cancer is the consequence of germline mutations in specific genes that increase one’s susceptibility to developing cancer . This susceptibility is transmitted from one family member to another in accordance with inheritance patterns. 

It is by means of genetic tests performed in the center that it is possible to discover the subjects who have a hereditary genetic predisposition to cancer and allows the patients to benefit from efficient means not only for early detection, but also the prevention of tumors. 

Within IOB, the Genetic Advisory Unit will perform an individual risk evaluation for each member of the family and the appropriate genetic tests.

Through these genetic counseling patients will receive information about: